D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

A new study suggests that generative AI has yet to develop the level of reasoning required for safe use in clinical settings. While recent systems show stronger performance when given detailed patient information, researchers found they still struggle with one of the most critical aspects of medical decision-making. The analysis, conducted by Mass General Brigham researchers, examined how large language models handle diagnostic tasks. Their findings, published in JAMA Network Open, indicate that these systems fall short when it comes to the complex thinking processes doctors rely on in real-world practice. According to co-author Marc Succi, current models are not suitable for independent clinical use. He pointed out that despite steady progress, these tools cannot yet match the reasoning involved in forming a differential diagnosis, a process he described as central to the practice of medicine. Among the strongest performers were newer models, including Claude 4.5 Opus, Grok 4, Gemini 3.0 variants, and GPT-5. Despite these advances, the study concluded that even the most capable systems still lack the depth of reasoning needed for safe, unsupervised use. The authors emphasized the continued importance of human oversight, warning that AI tools should support, not replace, clinical judgment. Experts not involved in the study echoed these concerns. They stressed that AI should not be used to make healthcare decisions without professional oversight and advised the public to seek qualified medical advice when dealing with health issues. Developers of cutting-edge tech software and hardware, like D-Wave Quantum Inc. (NYSE: QBTS), may not be surprised by these findings since AI models are only as good as the data they are trained on, and the system keeps improving as more data becomes available. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $21.69, up 0.7899628%, on 46,076,247 volume. The average volume for the last 3 months is 26,823,621 and the stock's 52-week low/high is $5.97/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Study Finds AI Medical Diagnosis Errors Exceed 80%
• OpenAI Receives $122B Funding to Advance its AI Projects
• Chinese Companies Are Using AI to Track American War Moves, Report

Rail Vision Ltd. (NASDAQ: RVSN)

The QualityStocks Daily Newsletter would like to spotlight Rail Vision Ltd. (NASDAQ: RVSN).

Amid increased demand for advanced collision-avoidance systems as rail networks grow more complex, Rail Vision’s (NASDAQ: RVSN) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological response. “Rail Vision develops vision-based detection systems designed to improve railway safety and operational performance, offering real-time obstacle detection and situational awareness that align closely with evolving safety priorities across the industry,” reads a recent article.“Rail Vision’s AI-powered electro-optical sensor systems are designed to address key railway safety challenges by integrating wide-field and narrow-field electro-optic cameras to provide a complete ‘safety envelope’ around the train. The company’s solutions include the use of thermal cameras that detect thermal signatures of workers, proprietary deep learning algorithms that distinguish between track infrastructure and human beings or other obstacles in real-time, and visual and acoustic alerts that provide critical awareness to operators, enabling immediate response to potential collisions and track hazards. These innovative systems are engineered to operate effectively in a wide range of environmental conditions, including low visibility, darkness and harsh weather, helping to overcome the limitations of human sight and improve overall situational awareness.”

To view the full article, visit https://ibn.fm/mRgCK

Rail Vision Ltd. (NASDAQ: RVSN) is an early commercialization-stage technology company developing unique rail-specific detection systems designed to improve safety and operational performance across global railway networks. The company’s products address visibility, hazard detection, and situational awareness challenges, which are critical for preventing collisions, reducing operational risks, and improving overall railway efficiency in diverse and demanding environments.

Rail Vision’s technology combines electro-optical sensors with artificial intelligence to extend real-time awareness along and around rail tracks under a wide range of operating conditions. The company aims to support safer train movement, improve operational reliability, and enhance decision-making for both manned and increasingly automated rail systems.

Rail Vision aims to deliver measurable safety, efficiency, and cost benefits for passenger and freight operators, while contributing to the continued evolution of modern rail infrastructure.

The company is headquartered in Ra’anana, Israel.

Products

Rail Vision offers two primary rail-deployed systems, MainLine and ShuntingYard, designed for distinct operating environments, along with a cloud-based operational intelligence dashboard that extends system functionality through data analysis and reporting.

• The MainLine system provides extended forward-looking visibility of up to 1.2 miles along open rail corridors, enabling real-time detection and classification of obstacles, hazards, and track-related events across a wide range of weather and lighting conditions. Designed for continuous operation, the system delivers real-time alerts that enhance driver awareness, improve safety, and increase operational efficiency.
• The ShuntingYard system detects hazards and provides visibility of up to 200 yards under diverse weather and lighting conditions along rail yards. The system offers front-to-back visual coverage, wide-view coupling cameras, and path-finding capabilities to support safe maneuvering in dense, low-speed operational settings.

Both systems are complemented by visual and acoustic alerts intended to reduce collision risk, minimize operational downtime, and improve efficiency during complex operations.

Rail Vision also offers a cloud-based SaaS intelligence portal that aggregates and analyzes data generated by Rail Vision’s products. This platform is designed to empower operators with the tools they need to efficiently manage their fleets, review historical data, and generate comprehensive reports, ultimately reducing downtime, lowering costs, and integrating Rail Vision’s data outputs with existing or future big data environments.

Additional offerings include system software updates, parts and repairs, support services, and tailored integrations.

Market Opportunity

Rail Vision operates within a growing global market driven by increasing demand for railway safety, operational efficiency, and automation. According to Research and Markets, the train collision avoidance systems market was estimated at approximately $20.3 billion in 2024 and is projected to reach $57.8 billion by 2030, representing a compound annual growth rate of 19.0% over that period. This growth reflects heightened focus on accident prevention, infrastructure modernization, and regulatory emphasis on safety.

In parallel, the global autonomous train market was estimated at $9.82 billion in 2023 and is expected to reach $14.50 billion by 2030, growing at a CAGR of 5.9% from 2024 to 2030, according to Grand View Research. Market trends supporting these opportunities include expansion of global rail networks, rising adoption of artificial intelligence and cloud-based services in railway operations, and increased investment in research and innovation related to AI-enabled rail technologies. Together, these dynamics position Rail Vision within markets that are expanding in both scale and technological sophistication.

Leadership Team

David BenDavid, Chief Executive Officer, is a technology executive with more than 25 years of global experience driving innovation across artificial intelligence, cloud computing, and advanced engineering platforms. Prior to joining Rail Vision, he served as CEO and co-founder of Tensorleap, where he led the development of a deep learning analytics platform focused on transparency and performance in AI model deployment.

Ofer Naveh, Chief Financial Officer, brings more than 20 years of experience in accounting and financial management, including roles at KPMG’s audit practice and in senior finance positions at publicly traded companies in Israel and the United States. He holds a B.A. in Accounting and Business and an M.A. in Law.

Noam Shloper, Chief Operating Officer, has more than 20 years of experience in executive compliance, quality management, and project management across military and commercial high-technology environments. He previously served in senior quality and operations roles at DRS Rada Technologies and Logic Industries and holds a degree in Industrial and Management Engineering.

Doron Cohadier, Vice President of Business Development and Marketing, has over two decades of managerial experience in business development and marketing within advanced technology sectors. His background includes senior leadership roles at Foresight Autonomous Holdings and Elbit Systems, supporting global commercialization of vision and defense technologies.

Amit Klir, Vice President of Research and Development, has extensive experience leading multidisciplinary engineering teams and managing the development of products combining video processing, signal processing, and advanced algorithms. He holds a B.Sc. in Electrical and Computer Engineering with a specialization in digital signal processing.

Rail Vision Ltd. (NASDAQ: RVSN), closed Friday's trading session at $8.36, up 0.1197605%, on 8,106 volume. The average volume for the last 3 months is 21,133 and the stock's 52-week low/high is $3.66/$29.571.

Recent News

• Rail Vision Ltd. (NASDAQ: RVSN) - AINewsBreaks - Rail Vision Ltd. (NASDAQ: RVSN) Deploys AI, Thermal Imaging to Redefine Rail Safety
• Safe Pro Group Inc. (NASDAQ: SPAI) Appoints Chief Operating Officer, Is Also Awarded Government Support Order for its Edge Processing Solution
• Rail Vision Ltd. (NASDAQ: RVSN) Positions AI-Powered Collision Avoidance Tech as Solution to Rail Safety Mandates

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

The QualityStocks Daily Newsletter would like to spotlight LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT).

• Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types
• First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity
• Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high

Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug regimens targeting different biological pathways are delivering results that single agents cannot. Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is advancing a first-in-class compound designed to fit directly into that model. Rather than developing a standalone therapy, the company is focused on enhancing the effectiveness of existing treatments, specifically chemotherapy and immunotherapy, across a broader range of patients.

Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma.”

To view the full article, visit https://ibn.fm/iCydh

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice.

Alongside internal development, LIXTE has pursued selective strategic actions that extend its capabilities beyond drug development, supporting its evolution into a platform-oriented oncology company spanning both pharmaceutical and technology-driven approaches.

The company is headquartered in Boca Raton, Florida.

Portfolio

LB-100 (PP2A Inhibitor Platform)

LIXTE’s lead clinical candidate, LB-100, is a proprietary small-molecule inhibitor of protein phosphatase 2A (PP2A) designed to enhance the activity of chemotherapy and immunotherapy. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Ongoing trials include combinations of LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combination therapy with chemotherapy in advanced soft tissue sarcoma. These studies are being conducted in collaboration with leading academic cancer centers and industry partners, reflecting LIXTE’s emphasis on externally validated clinical execution.

Radiotherapy Platform Expansion (Liora Technologies)

In November 2025, LIXTE expanded beyond pharmaceuticals with the acquisition of Liora Technologies Europe Ltd., adding an electronically controlled proton therapy platform known as the LiGHT System. This acquisition established LIXTE’s entry into radiotherapy, complementing its drug development activities and creating optionality for future recurring revenue models tied to jointly operated treatment centers.

Market Opportunity

LIXTE is targeting cancers where existing therapies show limited durability due to resistance, toxicity constraints, or suboptimal patient response. Chemotherapy and immunotherapy are widely applicable across tumor types but remain constrained by these factors, creating an opportunity for approaches that improve efficacy without proportionally increasing toxicity.

The company’s clinical programs focus on ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, indications characterized by high unmet need and limited effective treatment options. Rather than reshaping oncology care, LIXTE is developing LB-100 to augment existing therapies, an approach that could support wider clinical use within established treatment pathways.

Leadership Team

Geordan Pursglove, Chairman, President and Chief Executive Officer, is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, capital markets, strategic growth initiatives, and operational leadership across both public and private companies. His background includes leadership roles across technology, logistics, customer experience, sports, and marketing, with a focus on scaling organizations, raising capital, and executing transformative strategies.

Bas van der Baan, Chief Scientific Officer, has more than 20 years of experience in biotechnology with a concentration in oncology and diagnostics. He previously served as Chief Clinical and Business Development Officer at Agendia, where he played a key role in initiating and executing clinical trials that supported the commercialization of precision molecular oncology diagnostics in both the U.S. and Europe.

Peter Stazzone, Chief Financial Officer, brings over two decades of financial management experience across publicly traded and privately held companies. His background includes leading capital raises, mergers and acquisitions, financial controls, and public company reporting, with prior CFO roles at companies including Beyond Commerce, Strainz, and Voice Telecom.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), closed Friday's trading session at $3.61, up 12.1118%, on 29,678 volume. The average volume for the last 3 months is 42,520 and the stock's 52-week low/high is $0.64/$6.26.

Recent News

• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) - MissionIRNewsBreaks - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
• Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built
• Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO)

The QualityStocks Daily Newsletter would like to spotlight Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO).

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.”

To view the full article, visit https://ibn.fm/MK1HR

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.

At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.

Cardio Diagnostics was founded to develop and commercialize clinical tests and data solutions that enable earlier detection and more precise management of cardiovascular disease across clinical and non-clinical settings.

The company is headquartered in Chicago, Illinois.

Portfolio

The company’s portfolio brings together epigenetic and genetic insights with artificial intelligence to generate actionable information for cardiovascular care. This approach underpins a suite of blood-based tests and platforms designed for use across both individual patient care and broader population health settings.

Epi+Gen CHD™

Epi+Gen CHD™ is a prescription-only blood test that assesses a patient’s three-year risk of a coronary heart disease (CHD) event, including heart attack and sudden death. The test evaluates three epigenetic and five genetic biomarkers and applies artificial intelligence to generate a personalized risk score. It is designed to assess risk regardless of the presence of traditional factors and is non-invasive, requiring no fasting or radiation. In clinical validation studies, the test has demonstrated approximately two times greater sensitivity than conventional risk calculators and enables ongoing monitoring through epigenetic biomarkers that can change in response to intervention.

PrecisionCHD™

PrecisionCHD™ is a prescription-only blood test that aids in the detection and management of coronary heart disease by identifying molecular signals associated with the condition. The test evaluates 10 epigenetic and six genetic biomarkers and uses artificial intelligence to determine whether a disease signal is present. It provides patient-specific insights into the molecular drivers of disease, supporting more individualized care decisions, and is designed to detect both obstructive and non-obstructive forms of CHD in a non-invasive manner.

HeartRisk™

HeartRisk™ is a population-level cardiovascular risk intelligence platform that integrates anonymized clinical, claims, industry, and geographic data to provide real-time insights into heart disease risk across defined populations. The platform enables organizations to quantify risk, project future healthcare costs, benchmark against peer groups, and track changes over time, supporting more informed planning and risk management strategies.

CardioInnovate360™

CardioInnovate360™ is a biopharma research platform that leverages artificial intelligence and epigenetics to support the discovery, development, and validation of cardiovascular therapies. The platform is designed to identify novel biomarkers and disease pathways, optimize clinical trial design through improved patient stratification, and enable the development of scalable, non-invasive diagnostic tools.

Market Opportunity

Cardiovascular disease (CVD) is the leading cause of death in the United States, responsible for nearly one in three deaths. It encompasses a range of conditions, including CHD, stroke, heart failure, and peripheral artery disease, and continues to represent a significant and persistent healthcare burden.

Coronary heart disease is the most common form of CVD and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. In the U.S., one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (INOCA), a subset of CHD.

Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. While an estimated 80–90% of cardiovascular disease is preventable through early detection and proactive management, traditional approaches can leave gaps, as approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%.

Leadership Team

Meesha Dogan, PhD, Chief Executive Officer and Co-Founder, has served as CEO and a director since inception and co-founded the company alongside Dr. Philibert. She has more than a decade of experience working at the intersection of artificial intelligence, epigenetics, and genetics, leading the development and commercialization of DNA-based cardiovascular tests. Dr. Dogan is an inventor on multiple granted and pending patents and holds a PhD in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from the University of Iowa.

Robert Philibert, MD, PhD, Chief Medical Officer and Co-Founder, has served as CMO and a director since inception and co-founded the company with Dr. Dogan. He is a professor at the University of Iowa with joint appointments across psychiatry, neuroscience, molecular medicine, and biomedical engineering, and has published more than 200 peer-reviewed manuscripts. Dr. Philibert has received numerous NIH grants and holds patents related to epigenetics, including work on behavioral biomarkers.

Tim Dogan, PhD, Chief Technology Officer, has served as CTO since May 2022 after joining the company in 2019 as its first employee. He played a key role in developing the company’s Integrated Multi-Omics Engine™ and is a co-inventor on multiple patent-pending technologies. Dr. Dogan holds a PhD and BSE/MS degrees in Mechanical Engineering from the University of Iowa.

Elisa Luqman, JD, MBA, Chief Financial Officer, has served as CFO since March 2021 and has experience in public company finance, compliance, and corporate governance. She has held senior leadership roles at Clinigence Holdings Inc. and currently serves as Chief Legal Officer (SEC) at Nutex Health Inc., overseeing SEC reporting and compliance. Ms. Luqman holds a JD and MBA in Finance from Hofstra University.

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), closed Friday's trading session at $2.01, up 2.551%, on 43,226 volume. The average volume for the last 3 months is 233,585 and the stock's 52-week low/high is $0.97/$17.388.

Recent News

• Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) - InvestorNewsBreaks - Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is 'One to Watch'
• BioMedNewsBreaks - Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Engages IBN to Support Corporate Communications Strategy
• Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is 'One to Watch'

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

• Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies.
• Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease.
• SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators.

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, reinforcing both the promise of the therapy and the company’s broader development strategy.

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Friday's trading session at $1.25, up 6.8376%, on 574,715 volume. The average volume for the last 3 months is 309,361 and the stock's 52-week low/high is $1/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
• Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
• Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes

To view the full press release, visit https://ibn.fm/9iNYY

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company pioneering a new approach to cardiac care by delivering hospital-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for real-time heart monitoring.

The company’s mission is to empower both patients and physicians with actionable cardiac data wherever symptoms begin, addressing a critical gap in the first hours of cardiac events. Through its connected cardiac care ecosystem, HeartBeam is establishing a new model for remote monitoring that deepens patient engagement and delivers more actionable insights for physicians. This approach is designed to obtain early diagnosis which could reduce time to treatment, improve outcomes, and lower costs across the healthcare continuum.

HeartBeam’s system aims to bring clinical-grade cardiac assessment into the home. HeartBeam is preparing for commercial launch as its 12-lead ECG synthesis software undergoes regulatory review, building on prior clearance of its 3D ECG system for arrhythmia assessment. The company plans to leverage its unique longitudinal ECG dataset and deep learning algorithms to advance predictive capabilities in the future.

HeartBeam is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship innovation is its credit card-sized, cable-free ECG device that collects heart signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Cleared by the FDA in December 2024 for arrhythmia assessment, the HeartBeam System enables patients to capture high-fidelity heart data during symptomatic episodes, even outside a clinical environment.

The company’s pending 12-lead ECG synthesis software, developed from the same 3D signal acquisition, successfully met clinical endpoints in the VALID-ECG study and is currently under FDA review for arrhythmia assessment. This software combined with an on-demand cardiologist reader service is expected to form the backbone of HeartBeam’s commercial launch strategy, providing patients with access to a synthesized 12-lead ECG outside of the traditional hospital setting and enabling physician interpretation of patient ECGs from anywhere.

From the core, the team is building an ecosystem that includes integration with wearables, automated arrhythmia assessments, AI-driven wellness features, community features and trending insights. The ecosystem is intended to drive adoption and increase the overall value of the HeartBeam System.

Artificial Intelligence and Predictive Analytics

To enhance its diagnostic capabilities, HeartBeam is developing AI-powered arrhythmia detection algorithms to be validated in collaboration with Mount Sinai Heart. In early testing, these deep learning algorithms achieved diagnostic accuracy comparable to standard 12-lead ECGs when classifying atrial fibrillation, atrial flutter, and sinus rhythm.

Additionally, HeartBeam’s AI engine has the potential to transform routine monitoring into predictive power in the future. The company’s platform enables frequent readings, building a unique longitudinal ECG dataset unique that no one else offers. By leveraging deep learning on the repeated measurements, there is an opportunity to develop predictive capabilities, such as screening for hidden cardiac conditions and forecasting risk of future events. The unique longitudinal dataset will create a defensible data moat as the company continues to advance its AI program.

Market Opportunity

HeartBeam is targeting a large unmet need in cardiac care by delivering hospital-grade ECG diagnostics to patients outside of traditional healthcare settings. Cardiovascular disease is the leading cause of death worldwide, yet most cardiac events occur at home, where standard 12-lead ECGs are not available, leading to costly delays in diagnosis and treatment. HeartBeam’s FDA-cleared 3D ECG technology is designed to close this critical gap with on-demand, remote diagnostic capabilities.

The company’s initial commercialization strategy focuses on two distinct U.S. entry markets. The first includes approximately 500,000 elevated-risk patients in concierge care settings, representing a $250 million to $500 million annual revenue opportunity. The second addresses a larger direct-pay segment of 2.6 million elevated-risk individuals, with potential revenues of $1.3 billion to $2.6 billion annually. Future expansion may include reimbursement-driven pathways through Medicare Advantage, providers, and payer partnerships.

HeartBeam anticipates annual subscription pricing between $500 and $1,000 per patient, with roughly 50% gross margins on device costs and 70%+ on recurring revenue. Based on a model using five U.S. regions, each with an estimated 75,000 eligible patients, HeartBeam projects that just 10% adoption would generate approximately $20 million in gross profit—enough to reach cash flow break-even under current pricing and margin assumptions. Over time, the company’s longitudinal ECG dataset and predictive AI capabilities are expected to deliver additional value to healthcare systems, research institutions, and life science partners.

Leadership Team

Robert Eno, Chief Executive Officer and Director, brings over 30 years of experience in the medical technology industry, including leadership roles at HeartFlow, OptiMedica, and NeoGuide Systems. He joined HeartBeam as President in January 2023 and was appointed CEO in October 2024, later joining the board in May 2025 to support commercial growth.

Branislav Vajdic, Ph.D., Founder and Chief Technology Officer, is a semiconductor and medtech innovator who previously led product design teams at Intel and founded NewCardio. He holds over 20 patents and is the original architect of HeartBeam’s core technology.

Tim Cruickshank, Chief Financial Officer, oversees financial strategy and capital allocation. He works closely with the leadership team to support commercialization while maintaining financial discipline aligned with key regulatory milestones.

Peter Fitzgerald, M.D., Ph.D., Chief Medical Advisor, is Director of the Center for Cardiovascular Technology at Stanford and a seasoned clinical trialist with over 175 studies and 650 publications. He has founded over 20 medtech companies and advises the FDA on digital health analytics.

Ken Persen, Chief Technology Officer, has more than 28 years of experience in cardiac rhythm management and digital health. He previously served as CTO and CEO at LIVMOR and held engineering roles at Cameron Health and Guidant.

HeartBeam Inc. (NASDAQ: BEAT), closed Friday's trading session at $0.92, up 13.5802%, on 7,614,464 volume. The average volume for the last 3 months is 962,556 and the stock's 52-week low/high is $0.54/$4.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - AINewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives
• AINewsBreaks - HeartBeam Inc.'s (NASDAQ: BEAT) 'Significant Turning Point' Spotlighted in Recent Article

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) , operating through its TechForce Robotics subsidiary, announced the execution of a strategic supply agreement with NUWA Robotics Corp. and Foxconn, marking its transition from development and pilot programs to commercial deployment of robotic platforms. The agreement establishes a framework for engineering, manufacturing and commercialization, with TechForce retaining exclusive intellectual property ownership while leveraging NUWA’s system integration expertise and Foxconn’s global manufacturing capabilities to scale production and support growing demand for its Robotics-as-a-Service model.

To view the full press release, visit https://ibn.fm/Zy1Kg

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

• Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
• Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

• Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
• Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
• Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

• Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
• Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
• Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Friday's trading session at $0.0269, off by 3.9286%, on 1,239,541 volume. The average volume for the last 3 months is 1,266,560 and the stock's 52-week low/high is $0.0112/$0.114.

Recent News

• Nightfood Holdings Inc. (OTCQB: NGTF) - AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Advances Commercialization With Robotics Supply Agreement
• TechMediaBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Featured In AINewsWire Editorial On AI And Robotics In Pharma Manufacturing
• AINewsBreaks - Nightfood Holdings Inc. (OTCQB: NGTF) Highlighted In Editorial On AI Robotics Driving Pharmaceutical Manufacturing Compliance

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF)

The QualityStocks Daily Newsletter would like to spotlight Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF).

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets.
• Lahontan is working to build value through continued drilling, metallurgical work and project advancement.
• The company is showing a steady stream of updates this year, including drilling and key financing.

Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle, a backdrop that helps explain why Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is drawing attention as it advances four gold and silver properties in Nevada’s Walker Lane, including its flagship Santa Fe Mine project.

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) is a Canadian mine development and exploration company advancing a portfolio of gold and silver assets in Nevada’s Walker Lane, one of the world’s most productive and mining-friendly regions. Through its U.S. subsidiaries, the company controls four gold and silver properties in Nevada, three of which are 100%-owned and one controlled via a low-cost option to acquire full ownership. With a clear near-term path to production, Lahontan is focused on unlocking oxide gold and silver value from past-producing, infrastructure-rich projects.

The company’s mission is to responsibly develop and expand its oxide resources while minimizing capital intensity and maximizing economic returns. Leveraging a strong technical team with a track record of advancing projects and building mines, Lahontan is focused on growing gold and silver resources and hitting permitting milestones across multiple sites. Its strategy prioritizes scalability, efficiency, and timely value realization for shareholders.

By maintaining full project ownership and a capital-light development model, Lahontan Gold is positioned to rapidly transition from development to production.

The company is headquartered in Toronto, Ontario.

Projects

Santa Fe Mine

The 26.4 km² Santa Fe Mine is Lahontan’s flagship asset and core development priority. A past-producing open-pit, heap-leach gold and silver operation, Santa Fe historically yielded more than 359,000 ounces of gold and 702,000 ounces of silver between 1988 and 1995. The site benefits from established infrastructure—including power, water, and road access—and more than 79% of its known resources are unencumbered by royalties.

A 2024 NI 43-101 resource estimate outlines 1.54 million ounces of gold equivalent (AuEq) in the Indicated category and 0.41 million ounces Inferred, all pit-constrained. Oxide resources average among the highest grades in the state and are distributed across five known deposits. A 2025 Preliminary Economic Assessment (PEA) projects strong economic returns, including an after-tax NPV5% of $200 million, a 34.2% internal rate of return (IRR), and average annual production of approximately 50,000 ounces AuEq over an eight-year mine life.

Permitting is well underway for both the Exploration and Mine Plans of Operation, covering over 12 km² and more than 700 drill holes. The company is targeting construction permits in late 2026 and continues to pursue oxide resource expansion and metallurgical optimization, particularly within the Slab-Calvada corridor.

West Santa Fe

West Santa Fe lies just 13 kilometers from the flagship and is being explored as a potential satellite operation. The project is defined by a shallow, oxide-dominant gold-silver system with a conceptual target of 0.5 to 1.0 million ounces AuEq based on historic drilling and recent surface sampling, which returned up to 2.61 g/t Au and 899 g/t Ag (14.6 g/t AuEq). A 6,300-meter Phase One reverse circulation drill program is scheduled for 2025 to validate historical data and support a maiden resource estimate. Development is streamlined under a low-cost option agreement and a rapid permitting path via Notice of Intent.

Moho and Redlich

The Moho and Redlich projects provide additional longer-term upside within Lahontan’s portfolio. Moho features high-grade, oxidized epithermal veins with historic production at grades of 20–25 g/t Au and 300 g/t Ag. A 2019 core drill program confirmed the presence of high-grade mineralization at depth. Redlich, located along trend from the historic Candelaria silver mine, hosts disseminated Ag mineralization in epithermal veins and hydrothermal breccias but remains untested by drilling. While no near-term programs are currently disclosed, both assets represent future exploration optionality.

Market Opportunity

Lahontan Gold operates in Nevada, consistently ranked the top global mining jurisdiction by the Fraser Institute due to its transparent permitting process, legal stability, and established infrastructure. Nevada produces over 4.5 million ounces of gold annually, generating approximately $9 billion in value, and ranks fifth globally in total gold production.

According to the World Gold Council, total gold demand in Q1 2025 reached 1,206 tonnes, up 1% year-over-year, marking the strongest first quarter since 2016. Central banks added 244 tonnes to reserves, a slight slowdown from the prior quarter but well within the strong buying range observed over the past three years. Meanwhile, silver demand is supported by strong industrial usage in solar panels, electric vehicles, and semiconductors, with long-term deficits forecast in the physical silver market.

With macro-driven demand for gold, technology-driven silver consumption, and strong institutional buying across both metals, Lahontan is uniquely positioned to capitalize through its portfolio of oxide-focused projects in a top-tier jurisdiction—offering near-term production potential and longer-term resource expansion.

Leadership Team

Kimberly Ann, Founder, CEO, President & Executive Chair, is a veteran mining executive with a track record of founding and scaling junior resource companies. She has raised over $210M in financing and led the $340M buyout of Prodigy Gold. Her prior roles include CFO of PPX Mining and founder of Latin America Resource Group, which merged with Carube Copper to form C3 Metals.

Brian Maher, Founder and VP of Exploration, is an economic geologist with more than 45 years of experience. He previously led Prodigy Gold as CEO, where he helped develop the Magino gold project before its $341M acquisition. His career includes senior roles at ASARCO, Hochschild Mining, and PPX Mining, where he oversaw exploration and production in the Americas.

John McNeice, Chief Financial Officer, is a Chartered Professional Accountant with three decades of experience in public company reporting. He has served as CFO for seven public resource companies and played a key role in Ur-Energy Inc.’s TSX IPO and $150M in financings. He also serves as CFO for Gold79 Mines, C3 Metals, and Northern Graphite Corp.

Lahontan Gold Corp. (OTCQB: LGCXF), closed Friday's trading session at $0.3184, up 12.5486%, on 1,261,159 volume. The average volume for the last 3 months is 1,095,290 and the stock's 52-week low/high is $0.0321/$0.3854.

Recent News

• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Gains Relevance as Inflation, Conflict and Central-Bank Demand Reshape Gold
• MiningNewsBreaks - Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Reports Strong Cyanide Extraction Results at West Santa Fe Project
• Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Strengthens Position in Growing Global Gold Cycle

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

A survey that was conducted toward the end of last year by Gallup and West Health found that a sizeable number of Americans are using AI to supplement their interactions with healthcare providers. However, the specifics of how people used these digital tools varied based on age groups, income level and motivations. The survey was carried out from October 27 to December 22 in 2025. A total of 5,500 adults participated in the poll that was designed to be nationally representative. Among those who had used AI in the last 30 days, 59% said they used AI tools to conduct research on their own prior to visiting their doctor. 56% said they used those tools to conduct research after their doctor’s visit. A smaller but notable fraction (14%) of survey respondents indicated that they resorted to AI tools after encountering cost barriers to see their doctor, while 16% said they turned to AI tools after being unable to access a medical professional. Lower income respondents (14%) had a higher tendency of resorting to AI after being unable to pay for visits to doctors. This is concerning because even if Americans sought AI advice on health-related matters, the survey revealed that 34% of all survey respondents don’t trust AI-generated advice, while 33% were non-committal on whether they trusted the advice provided. Only a paltry 4% expressed complete trust in AI-generated healthcare advice. This survey shows there is an increasing use of AI for healthcare purposes among recipients of medical care, so stakeholders such as Astiva Health and policymakers need to pay closer attention to this trend and find ways to minimize the possible drawbacks that could result from a huge chunk of the population increasingly using AI on matters of health. 

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News

• Astiva Health - Shares of Health Insurers Rally After CMS Bumps Up 2027 Rates
• Gallup Poll: Healthcare Returns to the Top of Americans’ Biggest Domestic Worries
• Policy Expert Offers Suggestions for Curbing US Health Care Costs

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

Despite strong support for fossil fuels under the Trump administration, renewable energy in the United States continued to expand last year, reaching new highs. Clean energy sources generated about 26% of the country’s electricity, which equates to enough power for more than 100 million homes for a year. Renewables also accounted for about 33% of total utility-scale capacity, highlighting their growing importance in the national energy mix. Interestingly, much of this growth has taken place in Republican-leaning states. Ohio, Texas, and Florida together contributed over 70% of newly added solar capacity last year. Projections from the U.S. Energy Information Administration indicate that around 93% of new electricity capacity in the near term will come from wind, solar, and battery storage. This reflects a long-term shift away from fossil fuels, particularly coal, whose production has fallen dramatically since 2000. Despite these challenges, legal action has helped reverse several restrictive measures. Courts have struck down bans on wind permits and ruled against cuts to clean energy funding, allowing multiple projects to proceed. Overall, renewable energy in the U.S. continues to grow despite political resistance. The key question now is not whether this transition will happen, but how quickly it will progress and how strongly it will be shaped by future policy decisions. Across the northern border, entities like MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) are seeking to bring to market another clean form of energy, geologic hydrogen. The coming years could therefore see countries having many alternative forms of renewable energy to address their different needs. 

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Friday's trading session at $1, off by 0.990099%, on 34,205 volume. The average volume for the last 3 months is 328,430 and the stock's 52-week low/high is $0.124/$1.3.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - Renewables on the Rise in the US Despite Opposition from Trump
• Japanese Engineers Tap Wastewater to Produce Clean Energy
• MiningNewsBreaks - MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Expands Saskatchewan Natural Hydrogen Portfolio with New Discovery Milestones

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)

The QualityStocks Daily Newsletter would like to spotlight SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF).

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) develops next-generation, GPS-free target acquisition system and autonomous navigation software for drones and edge devices. Its zero-signature technology delivers real-time detection, tracking, and behavioral insights without reliance on radar, lidar, or heavy sensors. The company’s platform transforms unmanned systems into autonomous tools capable of identifying and engaging targets in GPS-denied environments.

The company’s vision is to redefine situational awareness by merging advanced mathematics, AI modeling, and edge computing into a unified intelligence architecture. SPARC AI aims to empower defense, rescue, and commercial organizations to operate safely and effectively in signal-contested environments where traditional navigation systems fail.

Its mission is to build the world’s most trusted geolocation intelligence platform that operates without GPS, enabling seamless interoperability across air, land, and sea devices.

SPARC AI is headquartered in Toronto, Canada.

Technology

SPARC AI’s technology suite delivers precision target acquisition, navigation, and autonomous intelligence in environments where GPS and traditional sensors fail. At its core is the Target Acquisition System, a software-only solution that determines the geolocation of any visible object using camera telemetry data. By removing the need for specialized hardware like lasers, radar, or lidar, the platform reduces weight, power use, and cost. Built on advanced mathematical modeling, it constructs a 3D understanding of terrain and position, achieving GPS-level accuracy in a zero-signature configuration suited for defense, rescue, and commercial operations.

SPARC AI Mobile extends this capability to handheld and field-issued devices, allowing operators to mark and transmit target coordinates directly from smartphones or rugged tablets. Once a target is identified, the device relays the coordinates to a connected drone, which autonomously navigates to the location for reconnaissance or engagement. The mobile system maintains accuracy even in GPS-jammed or degraded environments, turning each device into a connected node within a broader distributed network.

The company’s GPS-Denied Navigation engine enables mission planning and execution without satellite signals. Operators can design flight paths, define perimeters, and simulate routes to identify optimal vantage points and minimize resource use. Counter-surveillance and threat-prediction tools model adversarial visibility, helping users avoid detection and maximize ground coverage. Together, these capabilities form the foundation of SPARC AI’s software architecture, providing the intelligence backbone for its integrated command platform.

Overwatch Target Intelligence

Overwatch unifies all SPARC AI technologies, including its Target Acquisition, Mobile, and Navigation systems, into a single mission-ready platform that fuses detection, classification, tracking, and navigation in real time. It transforms drones and robotic systems into fully autonomous intelligence assets by synchronizing data across connected devices. The platform’s zero-signature design ensures complete operational security, allowing defense and rescue teams to conduct surveillance, reconnaissance, and engagement without GPS or active sensors.

Within Overwatch, the ATLAS Visibility Intelligence Engine enhances mission planning and reconnaissance through 2D and 3D visualization. Users can simulate line-of-sight coverage from any altitude, identify unseen or occluded areas, and optimize routes for surveillance or search and rescue. Operating entirely through software, ATLAS produces high-fidelity visibility data without mapping drones or additional power consumption, providing a lightweight, silent, and sensor-free alternative to lidar-based systems.

The SPARC AI SDK and open API framework extend Overwatch’s interoperability. Developers can embed SPARC AI’s intelligence into third-party systems such as PX4- and ArduPilot-powered drones, the world’s most widely used open-source flight platforms. The SDK provides REST APIs with bindings for Python, C++, and JavaScript and supports hardware including NVIDIA Jetson, Qualcomm Robotics RB5, and Raspberry Pi. Through these integrations, Overwatch serves as the command and intelligence layer of SPARC AI’s ecosystem, linking distributed drones, sensors, and edge devices into a coordinated autonomous network that operates entirely without GPS.

Market Opportunity

SPARC AI operates within the rapidly expanding defense, security, and commercial drone markets projected to exceed $100 billion over the next decade. The company’s software-defined approach addresses the global demand for autonomous systems capable of performing in denied, degraded, intermittent, and limited (DDIL) environments, positioning SPARC AI at the forefront of next-generation geolocation and targeting solutions.

Fortune Business Insights projects the global commercial drone market will reach approximately $65.25 billion by 2032, while Grand View Research estimates the combined drone hardware and services market will grow to $163.6 billion by 2030. With its per-device subscription model and integration across drones and robotic systems, SPARC AI is structured to capture recurring revenue from this accelerating adoption of GPS-denied intelligence technologies.

Leadership Team

Anoosh Manzoori, CEO, brings extensive experience as a technology entrepreneur, investor, and director, having founded, scaled, and exited multiple high-tech companies. He has taken five companies public, served on seven public company boards, and invested in innovations spanning cloud, fintech, biotech, IoT, defense, and AI.

Justin Hanka, Director, is an investment banking professional with 25 years of experience in mergers and acquisitions and capital markets. He has held executive roles at high-growth companies including iSelect.com.au and Helpmechoose, achieving multiple successful exits.

Anthony Haberfield, Director, is an international financial services executive with 30 years of experience across the Asia Pacific region, specializing in strategy, transformation, procurement, and emerging technology.

SPARC AI Inc. (OTCQB: SPAIF), closed Friday's trading session at $2.13, up 12.5495%, on 157,221 volume. The average volume for the last 3 months is 68,560 and the stock's 52-week low/high is $0.0792/$2.9.

Recent News

• SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) - TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Targets Growth in Defense Sector with Strategic Appointment
• SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Advances Ukraine Defense Initiatives as Electronic Warfare Reshapes Battlefield
• TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Releases Updated Investor Presentation Highlighting Growth Strategy

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)

The QualityStocks Daily Newsletter would like to spotlight LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF).

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is a Canadian exploration and development company advancing the district-scale Swanson Gold Project in Québec’s prolific Abitibi Gold Belt and progressing toward the near-term restart of gold production at its wholly owned Beacon Gold Mill. The company’s strategy centers on consolidating strategic land packages—highlighted by its flagship Swanson Gold Project, a 160 km² district-scale property that includes several prospects rich in gold and critical metals previously held by Monarch Mining, Abcourt Mines, and Globex Mining. The company is leveraging its 100%-owned, fully permitted and recently refurbished Beacon Gold Mill to transition from explorer to near-term gold producer—a key inflection point that typically triggers a market re-rating, further bolstered by current rising gold market prices. By processing material from Swanson and offering custom milling to regional projects, LaFleur aims to generate cash flow with minimal capital outlay, targeting annual gold production of up to 15,000 to 20,000 ounces by early 2026.

LaFleur’s vision is to evolve into an intermediate gold producer by capitalizing on strong market conditions and Québec’s rich mining infrastructure. The location, in the world-class Abitibi Gold Belt, and its infrastructure advantage, positions LaFleur for regional consolidation, strategic partnerships, or acquisition interest. Its mission emphasizes efficient value creation through methodical exploration, low-cost asset advancement, and opportunistic acquisitions—including land and deposits from Monarch Mining, Abcourt Mines, and Globex Mining.

Québec ranks among the world’s top mining jurisdictions, offering access to flow-through capital and regulatory stability. LaFleur’s integrated strategy—combining exploration at Swanson, a permitted mill at Beacon, and potential custom milling agreements—supports a streamlined path to near-term production.

LaFleur Minerals is headquartered in Vancouver, British Columbia.

Projects

LaFleur Minerals’ operations focus on two strategically located assets in the Abitibi Gold Belt: the Swanson Gold Project and the Beacon Gold Mill and Mine. These projects leverage the region’s world-class mining infrastructure and high-grade gold potential to drive the company’s transition to production.

Swanson Gold Project

The Swanson Gold Project spans 16,600 hectares and hosts the Swanson, Bartec, and Jolin gold deposits along a major structural break in the Abitibi Gold Belt. The 2024 Mineral Resource Estimate for the Swanson deposit outlines 123,400 oz of gold in Indicated category (2.1 million tonnes at 1.8 g/t) and 64,500 oz in Inferred category (872,000 tonnes at 2.3 g/t). Located 66 km north of Val-d’Or, the Project is accessible by road and rail and benefits from more than 36,000 meters of historical drilling, along with existing infrastructure including an 80-meter decline portal.

Recent work—including airborne magnetics, soil sampling, and Induced Polarization surveys—has identified multiple high-priority targets and resulted in several high-grade gold assay results, including a grab sample grading 11.71 g/t Au at Jolin, which points to significant upside as the Company prepares to test multiple new zones.

LaFleur has defined over 50 drill targets at Swanson and nearby prospects (Bartec, Jolin, Marimac) and is completing a minimum 5,000-metre diamond drilling beginning in June 2025. LaFleur Minerals has also initiated permitting for a 100,000-tonne surface bulk sample averaging 1.89 g/t Au, which it plans to process at the Beacon Gold Mill as part of a near-term production strategy.

Beacon Gold Mill

LaFleur’s 100%-owned Beacon Gold Mill is a fully refurbished and permitted mill and tailings storage facility capable of processing 750 tonnes per day (tpd), with potential expansion to 1,800 tpd, with access to numerous nearby gold deposits that could be prime sources of ore. Located only 60 km from Swanson, it underwent a $20 million upgrade by Monarch Mining in 2022 and has been under care and maintenance since early 2023. LaFleur is finalizing a C$5-6 million restart plan, ramping up production by late 2025 into early 2026, processing Swanson mineralized material and assessing custom milling opportunities for regional deposits, creating multiple potential revenue streams.

The Beacon Gold Mill is a de-risked, proven asset that benefits from existing infrastructure, including access to roads, power, and skilled labor, and further enhances the overall value proposition of LaFleur by providing a clear path to production and potential revenue-generation.

Market Opportunity

LaFleur Minerals is targeting the gold mining and processing market in Québec’s Abitibi Gold Belt, one of the world’s most productive gold regions. Its fully permitted Beacon Gold Mill, with a 750 tpd capacity and authorization to process 1.8 million tonnes of tailings, is strategically positioned to handle material from LaFleur’s Swanson Gold Project and to offer custom milling for nearby deposits such as Granada Gold. The company projects annual production of over 30,000 ounces of gold once in full production, with potential for significant revenue generation based on prevailing market prices.

Global demand for gold remains robust, driven by geopolitical risk, inflation hedging, and central bank accumulation. The World Gold Council forecasts 3-5% annual demand growth through 2030, with average prices expected between $3,200 and $3,500/oz. Within this environment, Québec’s top-tier mining jurisdiction—ranked fifth globally by the Fraser Institute in 2023—offers streamlined permitting and access to flow-through capital. LaFleur’s low-cost Beacon restart (C$5-6 million) and proximity to more than 100 active and historical mines position the company to fill a growing need for small-to-medium scale custom milling.

At Swanson, LaFleur plans to grow its current 187,900-ounce resource toward 1 million ounces through its 2025 drilling program. This hub-and-spoke strategy, leveraging centralized milling and strong local infrastructure, reduces development risk and strengthens LaFleur’s foothold in one of the most attractive gold belts in the world.

Leadership Team

Kal Malhi, Chairman, is a successful entrepreneur and the Founder of Bullrun Capital Inc., where he has raised over $300 million for early-stage companies across the mining, oil and gas, biomedical, agriculture, and technology sectors. He specializes in advancing academic research into commercial ventures and public listings, with more than two decades of capital markets and leadership experience.

Paul Ténière, M.Sc., P.Geo., Chief Executive Officer, is a seasoned mining executive and Professional Geologist with over 25 years of global experience in the development of precious and base metals, critical minerals, and metallurgical coal projects. Mr. Ténière is an expert in NI 43-101 and S-K 1300 disclosure standards and has held senior roles including President & CEO, SVP Exploration, and Director with several publicly traded mining companies. Mr. Ténière also worked at the Toronto Stock Exchange (TSX) and TSX Venture Exchange as a mining expert and Senior Listings Manager listing dozens of mining companies and ensuring listed issuers met their corporate governance and compliance and disclosure requirements.

Harry Nijjar, Chief Financial Officer and Corporate Secretary, serves as Managing Director at Malaspina Consultants Inc., providing CFO and strategic financial advisory services to companies across multiple industries. He holds a CPA CMA designation from the Chartered Professional Accountants of British Columbia and a Bachelor of Commerce from the University of British Columbia.

Louis Martin, P.Geo., Technical Advisor and Exploration Manager, is a veteran geologist with more than 40 years of exploration experience. He has played key roles in significant gold and base metal discoveries, including the Louvicourt (1989) and West Ansil (2005) deposits—both recognized by the Association de l’Exploration Minière du Québec (AEMQ). He previously served as VP Exploration at Clifton Star Resources, where he led the pre-feasibility study for the 4.5 million-ounce Duparquet Gold Project. He is a registered geologist in Québec and Ontario.

Tara Asfour, Corporate Communications, Investor Relations and Strategy, is an experienced executive consultant with over 12 years of management, investor relations, communications and marketing experience, specialized in capital markets. In her previous positions, Ms. Asfour has led over US$550 million worth of fundraising and strategic development initiatives. Ms. Asfour holds a Master’s degree in Business Management, a Financial Markets Certificate from Yale University, and a Certificate in Alternative Investments from HBS. Previous positions include investor relations executive at Red Pine Exploration, Fancamp Exploration, Communications Director at Dominion Water Reserves (now Prime Drink Group Corp) and advisor to various other publicly listed firms in the resource and technology sectors. Ms. Asfour holds the Institute for Governance (IGOPP) Certification in Governance, Ethics in Business Environment and Corruption Prevention.

Peter Espig, Strategic Advisor and Consultant, has served as Vice-President at Goldman Sachs Japan in both the Principal Finance and Securitization Group and the Asia Special Situations Group, where his team participated in more than $10 billion in structured deals, capital raises, and cross-border transactions. Prior to Goldman Sachs, he was Vice-President at Olympus Capital, a New York-based private equity firm, where he focused on corporate restructurings, investment analysis, and international financing negotiations. He also played a pioneering role in some of the earliest SPAC transactions, totaling over US$1.2 billion, and brings deep experience in disciplined capital deployment and turnaround execution. Since 2013, Mr. Espig has served as President and CEO of Nicola Mining Inc. and is a board member of ESGold Corp and First Lithium Minerals. Mr. Espig holds a Bachelor of Arts from the University of British Columbia and an MBA from Columbia Business School, where he was a Chazen International Scholar. He has served on various public boards and was recognized among Industry Era’s “Top 10 Admired Leaders” in 2023.

Jean Lafleur, Senior Technical Advisor, is a Professional Geologist (Québec) with 45 years of experience in Canada and internationally including USA, Mexico, Latin America, Ireland, Spain and Africa. Earlier in his career he worked with Newmont, Falconbridge, Dome Mines, and Placer Dome and has been a C-suite executive for a number of junior exploration companies. Jean has remained active as a technical, management, and financing consultant with junior explorers since the early 2000’s through his own geological consultancy firm and throughout his career has led a number of teams in the discovery of precious and base metals, nickel, PGE’s, uranium, and iron deposits. Jean’s expertise includes mining company and project evaluations, audits, technical reporting, exploration program planning and execution, and research and development with a strong focus on Québec. Jean currently acts as a Senior Consultant, North America for Appian Capital Advisory LLP, a mining-focused private equity firm based in London, UK where through his extensive professional network he sources and presents potential mining transactions in North America to the Appian team for investment opportunities.

LaFleur Minerals Inc. (OTCQB: LFLRF), closed Friday's trading session at $0.49, up 10.1124%, on 61,480 volume. The average volume for the last 3 months is 150,890 and the stock's 52-week low/high is $0.0631/$0.62.

Recent News

• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) - MiningNewsBreaks - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Secures Up to C$30 Million Prepayment Facility and Offtake Agreement With Trafigura
• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Nears Restart of Gold Production this Quarter with First Gold Pour on the Horizon
• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Bolsters Report on Positive PEA, Nears Gold Production